A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

Trial Profile

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

Suspended
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs ICT 107 (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms STING
  • Sponsors ImmunoCellular Therapeutics
  • Most Recent Events

    • 20 Jul 2017 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
    • 19 Jul 2017 This trial has been discontinued in Austria according to European Clinical Trials Database record.
    • 12 Jul 2017 This trial has been discontinued in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top